The Synthesis of Nano-Doxorubicin and its Anticancer Effect

Author(s):

Lusha Zhu and Mei Lin*   Pages 2466 - 2477 ( 12 )

Abstract:

Doxorubicin (DOX) is widely used as a clinical first-line anti-cancer drug. However, its clinical application is severely limited due to the lack of tumor specificity of the drug and severe side effects such as myelosuppression, nephrotoxicity, dose-dependent cardiotoxicity, and multi-drug resistance. To improve the bioavailability of DOX, maximize the therapeutic effect, and reduce its toxicity and side effects, many studies have been done on the nanoformulations of DOX, such as liposomes, polymer micelles, dendrimer, and nanogels. Herein, we review the latest progress of DOX nano-preparations and their anti-tumor effects, hoping to provide theoretical references and new research ideas for the development of new dosage forms of the drug and the technical methods available for clinical application.

Keywords:

Doxorubicin, nanotechnology, nanoparticles, synthesis, nanocarrier, drug delivery systems.

Affiliation:

Department of Science and Research, Taizhou People’s Hospital, The Fifth Affiliated Hospital of Nantong University, Taizhou 225300, Department of Science and Research, Taizhou People’s Hospital, The Fifth Affiliated Hospital of Nantong University, Taizhou 225300

Graphical Abstract:

Read Full-Text article